SUBSCRIBE
SUBSCRIBE

Alnylam Pharmaceuticals

NEWS
Amneal and Impax to Marry, Creating the 5th Larges
Biotech Bay
Top 3 Biotech Stocks to Buy in 2018
Here’s a look at three promising biotech stocks.
December 7, 2017
 · 
3 min read
Ignyta Stock Booms on Promising Mid-Stage Lung Can
Drug Development
ASH Heats Up, Plus Alkermes’ Huge I-Told-Ya-So
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
Drug Development
Alnylam Gets VIP Status as the FDA Slaps Breakthrough Tag on Patisiran
The company is weeks away from completing its rolling NDA for Patisiran.
November 20, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
Alnylam Emerges as Winner in Rare Disease Study Showdown With Ionis
Alnylam and Sanofi Genzyme presented positive Phase III results of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy at a conference in France.
November 2, 2017
 · 
3 min read
 · 
Mark Terry
Business
Alnylam Jumps on $1B RNAi Pact With Vir Biotechnology
Alnylam and startup Vir Biotech inked a deal worth up to $1B for the development and marketing of RNAi therapies aimed at treating infectious diseases including HBV.
October 18, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
BioPharm Executive: From the Bench to the Clinic
Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi
Business
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam
September 21, 2017
 · 
2 min read
Alnylam Stock Craters After Deaths Cause Clinical Trial to End
Drug Development
Alnylam Stock Catapults as Genetic Disease Drug Meets All Phase III Goals
September 20, 2017
 · 
3 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Drug Development
Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges
September 7, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Drug Development
Alnylam Presents Positive Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran
April 19, 2021
 · 
16 min read
Business
Alnylam to Webcast Conference Call Discussing First Quarter 2021 Financial Results
April 15, 2021
 · 
2 min read
Drug Development
Alnylam Presents Positive Late-Breaking Data from Ongoing Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
April 11, 2021
 · 
11 min read
Genetown
Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Conference
April 6, 2021
 · 
2 min read
Drug Development
Alnylam Announces Publication of ILLUMINATE-A Phase 3 Study Results for Lumasiran in The New England Journal of Medicine
March 31, 2021
 · 
12 min read
Genetown
Alnylam to Webcast Presentation at Stifel 3rd Annual CNS Day
March 29, 2021
 · 
1 min read
Genetown
Alnylam to Present Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the American Academy of Neurology Virtual Annual Meeting 2021
March 23, 2021
 · 
13 min read
Genetown
Alnylam Issues Inaugural Corporate Responsibility Summary
March 11, 2021
 · 
8 min read
Genetown
Alnylam to Webcast Presentations at Upcoming March 2021 Investor Conferences
February 22, 2021
 · 
2 min read
Genetown
Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021
 · 
2 min read
Load More